Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study

James Hawkins; Kirsten Hakala; Michael B. Heller; Richard M. Kaplan; Sandra Schneider; Ronald D. Stewart

doi:10.1016/0736-4679(86)90001-6

Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study

James Hawkins, Kirsten Hakala, Michael B. Heller, Richard M. Kaplan, Sandra Schneider, Ronald D. Stewart

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

4 Citas (Scopus)

Resumen

The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β₂-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid® reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.

Idioma original	English
Páginas (desde-hasta)	273-277
Número de páginas	5
Publicación	Journal of Emergency Medicine
Volumen	4
N.º	4
DOI	https://doi.org/10.1016/0736-4679(86)90001-6
Estado	Published - 1986
Publicado de forma externa	Sí

ASJC Scopus Subject Areas

Emergency Medicine

Acceder al documento

10.1016/0736-4679(86)90001-6

Otros archivos y enlaces

Citar esto

@article{3b09d9f59f4f414e82d3de3a8b5d0437,

title = "Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study",

abstract = "The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β2-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid{\textregistered} reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.",

author = "James Hawkins and Kirsten Hakala and Heller, {Michael B.} and Kaplan, {Richard M.} and Sandra Schneider and Stewart, {Ronald D.}",

year = "1986",

doi = "10.1016/0736-4679(86)90001-6",

language = "English",

volume = "4",

pages = "273--277",

journal = "Journal of Emergency Medicine",

issn = "0736-4679",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Metered-dose aerosolized bronchodilators in prehospital care

T2 - A feasibility study

AU - Hawkins, James

AU - Hakala, Kirsten

AU - Heller, Michael B.

AU - Kaplan, Richard M.

AU - Schneider, Sandra

AU - Stewart, Ronald D.

PY - 1986

Y1 - 1986

N2 - The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β2-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid® reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.

AB - The prehospital use of aerosolized bronchodilators was studied in 50 adult patients with bronchospasm. The specific β2-agonist, albuterol, was discharged from a metered-dose inhaler (MDI) into the Inhal-aid® reservoir-delivery device. No serious adverse effects were encountered, although a substantial proportion of the patients (36%) had difficulty utilizing the device. Ability to use the system properly correlated with improvement in symptoms; inability to use the device was most clearly related to severity of clinical presentation. It is concluded that the use of aerosolized bronchodilators is feasible in prehospital care and most useful in patients with mild or moderately severe symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0022974501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022974501&partnerID=8YFLogxK

U2 - 10.1016/0736-4679(86)90001-6

DO - 10.1016/0736-4679(86)90001-6

M3 - Article

C2 - 3540093

AN - SCOPUS:0022974501

SN - 0736-4679

VL - 4

SP - 273

EP - 277

JO - Journal of Emergency Medicine

JF - Journal of Emergency Medicine

IS - 4

ER -

Metered-dose aerosolized bronchodilators in prehospital care: A feasibility study

Resumen

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto